Aurobindo Pharma is under the scrutiny of the US FDA once again. According to published reports, 3-4 inspectors from the U.S. FDA recently completed their inspection of the company’s Unit IV in Telangana, India and this week are at the biopharma’s Units V and VIII sites in Hyderabad. Spread over 33 acres, Aurobindo’s Unit-IV is a dedicated mid-size manufacturing facility for generic sterile injectables, opthalmics and low volume parenterals. By contrast the facilities under the FDA lens this week, Units V and VIII, are smaller facilities that manufacture antibiotics, ARVs, CVSs and CNSs. Learn More